Biofil Chemicals and Pharmaceuticals Limited
NSE: BIOFILCHEM BSE: BIOFILCHEM
NSE
46.99
0.76 (1.64%)
Prev Close
46.23
Open Price
45.2
Volume
4,607
Today Low / High
45.2 / 47.4
52 WK Low / High
40.4 / 91.87
Range
45 - 49
BSE
47.14
0.45 (0.96%)
Prev Close
46.69
Open Price
46
Volume
1,644
Today Low / High
45.76 / 48.5
52 WK Low / High
40.5 / 92
Range
45 - 49
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 46.99 (target range: 45 - 49), reflecting a change of 0.76 (1.64395%). On the BSE, it is listed at 47.14 (target range: 45 - 49), showing a change of 0.45 (0.9638%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
11 Jul
45.20
3.96%
10 Jul
47.05
-1.74%
09 Jul
46.00
0.80%
08 Jul
47.88
-2.09%
07 Jul
45.21
2.37%
04 Jul
46.00
2.13%
03 Jul
45.79
2.64%
02 Jul
45.25
1.19%
01 Jul
47.17
-0.36%
30 Jun
45.50
3.67%
27 Jun
47.50
-0.76%
26 Jun
47.50
-0.51%
25 Jun
45.85
3.56%
24 Jun
46.67
-1.54%
23 Jun
45.00
4.24%
20 Jun
47.00
-1.09%
19 Jun
48.00
-3.27%
18 Jun
50.00
-2.32%
17 Jun
50.02
-2.18%
16 Jun
49.20
1.67%
Biofil Chemicals and Pharmaceuticals Limited Graph
Biofil Chemicals and Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Biofil Chemicals and Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 46.99, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 47.14 | 47.61 | 42.85 - 52.37 |
| 48.08 | 38.47 - 57.70 | ||
| 48.55 | 33.99 - 63.12 | ||
| Bearish Scenario | 47.14 | 46.67 | 42.00 - 51.34 |
| 46.20 | 36.96 - 55.44 | ||
| 45.73 | 32.01 - 59.44 |
Overview of Biofil Chemicals and Pharmaceuticals Limited
ISIN
INE829A01014
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
30,911
Market Cap
764,705,862
Last Dividend
0
Official Website
IPO Date
2017-07-27
DCF Diff
47.37
DCF
0
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 33.40 Cr | 31.31 Cr | 2.09 Cr | 0.0626 | 0.00 Cr | 0.42 Cr | 0.47 Cr | 0.56 Cr | 0.34 | 1.15 Cr | 0.0167 |
| 2024-03-31 | 40.04 Cr | 37.51 Cr | 2.53 Cr | 0.0631 | 0.00 Cr | 0.14 Cr | 0.42 Cr | 0.71 Cr | 0.44 | 1.31 Cr | 0.0177 |
| 2023-03-31 | 30.04 Cr | 27.47 Cr | 2.56 Cr | 0.0853 | 0.00 Cr | 0.14 Cr | 0.74 Cr | 0.56 Cr | 0.34 | 1.26 Cr | 0.0187 |
| 2022-03-31 | 22.38 Cr | 19.52 Cr | 2.87 Cr | 0.1280 | 0.00 Cr | 0.19 Cr | 0.91 Cr | 0.70 Cr | 0.43 | 1.48 Cr | 0.0312 |
| 2021-03-31 | 35.75 Cr | 32.48 Cr | 3.27 Cr | 0.0914 | 0.01 Cr | 0.18 Cr | 1.19 Cr | 1.24 Cr | 0.76 | 2.40 Cr | 0.0347 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.13 Cr | 50.96 Cr | 32.18 Cr | 18.7816 Cr | 0.47 Cr | 0.34 Cr | 3.34 Cr | 8.34 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 31.8477 Cr |
| 2024-03-31 | 2.28 Cr | 47.08 Cr | 28.88 Cr | 18.2028 Cr | 0.44 Cr | -1.84 Cr | 2.55 Cr | 8.62 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 28.5245 Cr |
| 2023-03-31 | 0.03 Cr | 31.41 Cr | 14.10 Cr | 17.3015 Cr | 0.52 Cr | 0.48 Cr | 1.21 Cr | 9.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 13.7255 Cr |
| 2022-03-31 | 0.15 Cr | 18.73 Cr | 1.89 Cr | 16.8377 Cr | 0.46 Cr | 0.32 Cr | 1.29 Cr | 9.42 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 1.4947 Cr |
| 2021-03-31 | 0.44 Cr | 33.24 Cr | 17.11 Cr | 16.1291 Cr | 0.43 Cr | -0.01 Cr | 4.34 Cr | 9.78 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 16.7531 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -1.9236 Cr | -0.1001 Cr | -0.0045 Cr | -2.0237 Cr | -2.0282 Cr | 0.2553 Cr | -0.1001 Cr | 0.7362 Cr | 0.0324 Cr | 0.0000 Cr | -0.7917 Cr |
| 2024-03-31 | 2.3937 Cr | -0.0229 Cr | -0.1249 Cr | 2.3708 Cr | 2.2459 Cr | 2.2835 Cr | -0.0229 Cr | 0.7092 Cr | -0.0834 Cr | 0.0000 Cr | -1.3363 Cr |
| 2023-03-31 | -0.1118 Cr | -0.0106 Cr | 0.0151 Cr | -0.1224 Cr | -0.1073 Cr | 0.0376 Cr | -0.0106 Cr | 0.7930 Cr | 0.0576 Cr | 0.0000 Cr | 0.0797 Cr |
| 2022-03-31 | -0.2199 Cr | -0.0699 Cr | -0.0058 Cr | -0.2898 Cr | -0.2956 Cr | 0.1449 Cr | -0.0699 Cr | 0.6984 Cr | 0.0348 Cr | 0.0000 Cr | 3.0514 Cr |
| 2021-03-31 | 1.1109 Cr | -0.0961 Cr | -0.8303 Cr | 0.5442 Cr | 0.1845 Cr | 0.4405 Cr | -0.5667 Cr | 1.9189 Cr | -0.7622 Cr | 0.0000 Cr | -2.6524 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 8.35 Cr | 7.80 Cr | 0.55 Cr | 0.0655 | 0.02 Cr | 0.20 Cr | 0.12 | 0.34 Cr | 0.0239 |
| 2024-12-31 | 14.20 Cr | 13.62 Cr | 0.57 Cr | 0.0403 | 0.21 Cr | 0.16 Cr | 0.10 | 0.33 Cr | 0.0116 |
| 2024-09-30 | 2.41 Cr | 2.05 Cr | 0.36 Cr | 0.1505 | 0.03 Cr | 0.02 Cr | 0.02 | 0.14 Cr | 0.0101 |
| 2024-06-30 | 8.44 Cr | 7.72 Cr | 0.73 Cr | 0.0862 | 0.59 Cr | 0.17 Cr | 0.10 | 0.34 Cr | 0.0201 |
| 2024-03-31 | 15.20 Cr | 15.01 Cr | 0.19 Cr | 0.0127 | -0.11 Cr | 0.25 Cr | 0.15 | 0.37 Cr | 0.0164 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.13 Cr | 0.12 Cr | 0.26 Cr | 38.32 Cr | 3.34 Cr | 42.55 Cr | 8.34 Cr | 50.96 Cr | 32.18 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 0.22 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -18.40 Cr |
| 2024-09-30 | 0.16 Cr | 0.06 Cr | 0.22 Cr | 25.51 Cr | 6.80 Cr | 33.61 Cr | 8.43 Cr | 42.04 Cr | 23.64 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 2.28 Cr | 0.00 Cr | 0.00 Cr | 2.28 Cr | 0.00 Cr | 0.00 Cr | -18.20 Cr |
| 2024-03-31 | 2.28 Cr | 2.19 Cr | 2.28 Cr | 33.03 Cr | 2.55 Cr | 38.41 Cr | 8.62 Cr | 47.08 Cr | 28.88 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 0.16 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 0.02 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 0.17 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 0.25 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 0.09 Cr | 0.21 Cr | 0.00 Cr | 0.00 Cr | 0.21 Cr | 0.27 Cr | 0.06 Cr | 0.00 Cr | 0.21 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,672.00 | ₹4,011,596,160,000.00 | ₹1,298,300.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,835.00 | ₹1,814,480,615,000.00 | ₹224,031.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,314.20 | ₹1,121,674,419,000.00 | ₹344,196.00 |
| Mankind Pharma Limited | MANKIND | ₹2,578.30 | ₹1,064,138,561,908.00 | ₹2,780,363.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,254.70 | ₹1,044,010,449,778.00 | ₹895,308.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹979.60 | ₹985,702,908,000.00 | ₹921,030.00 |
| Lupin Limited | LUPIN | ₹1,894.70 | ₹865,339,805,200.00 | ₹1,511,045.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,124.80 | ₹653,286,089,600.00 | ₹1,058,782.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,181.10 | ₹615,508,601,100.00 | ₹15,678,334.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,806.70 | ₹574,713,085,500.00 | ₹183,070.00 |
| Laurus Labs Limited | LAURUSLABS | ₹790.20 | ₹426,117,720,600.00 | ₹1,475,669.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹1,017.95 | ₹389,434,085,794.00 | ₹322,114.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,449.60 | ₹367,769,318,400.00 | ₹119,065.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,626.50 | ₹328,081,368,000.00 | ₹236,895.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,757.10 | ₹285,491,850,900.00 | ₹3,159,181.00 |
| Piramal Enterprises Limited | PEL | ₹1,217.50 | ₹275,980,465,000.00 | ₹2,508,249.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,608.60 | ₹251,036,507,400.00 | ₹444,444.00 |
| Eris Lifesciences Limited | ERIS | ₹1,709.80 | ₹232,869,630,600.00 | ₹106,770.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,241.50 | ₹231,037,500,000.00 | ₹20,847.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹976.60 | ₹191,963,425,800.00 | ₹60,016.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,165.70 | ₹185,673,861,700.00 | ₹144,076.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹961.80 | ₹172,267,998,000.00 | ₹1,353,979.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,301.00 | ₹157,820,599,900.00 | ₹74,663.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,023.30 | ₹153,794,472,610.00 | ₹35,929.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹469.00 | ₹113,800,036,000.00 | ₹331,193.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,755.50 | ₹95,537,846,700.00 | ₹23,112.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹896.75 | ₹87,693,989,575.00 | ₹154,034.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹927.20 | ₹84,036,419,664.00 | ₹291,915.00 |
| Strides Pharma Science Limited | STAR | ₹887.80 | ₹81,822,045,060.00 | ₹428,094.00 |
| FDC Limited | FDC | ₹501.35 | ₹81,624,793,500.00 | ₹72,209.00 |
| Suven Life Sciences Limited | SUVEN | ₹276.63 | ₹60,325,810,620.00 | ₹285,602.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹159.34 | ₹51,709,335,480.00 | ₹1,252,722.00 |
| Innova Captab Limited | INNOVACAP | ₹875.40 | ₹50,094,703,722.00 | ₹46,543.00 |
| Sequent Scientific Limited | SEQUENT | ₹184.32 | ₹46,136,217,600.00 | ₹343,582.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹473.60 | ₹43,225,472,000.00 | ₹158,284.00 |
| Hikal Limited | HIKAL | ₹340.50 | ₹41,983,990,500.00 | ₹164,468.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,526.20 | ₹41,780,821,800.00 | ₹17,230.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹590.85 | ₹41,599,266,930.00 | ₹17,355.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹718.30 | ₹36,431,529,530.00 | ₹55,088.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹349.05 | ₹35,002,035,900.00 | ₹50,065.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹62.67 | ₹34,340,277,180.00 | ₹1,978,828.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹664.85 | ₹32,014,522,050.00 | ₹589,436.00 |
| Indoco Remedies Limited | INDOCO | ₹326.45 | ₹30,114,326,955.00 | ₹174,646.00 |
| Alembic Limited | ALEMBICLTD | ₹117.26 | ₹30,110,257,203.00 | ₹332,328.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹91.18 | ₹26,763,791,860.00 | ₹1,225,212.00 |
Key Executives
Chief Operating Officer & Whole Time Director
Mr. Ketan Shah
Gender: male
Year Born: 1961
Head of Administration
Joseph Chacko
Gender: Not Specified
Year Born: 1961
Chief Chemist
Vinayak Bhopte
Gender: Not Specified
Year Born: 1974
Chief Financial Officer
Mr. Pavan Singh Rajput
Gender: male
Year Born: 1991
FAQs about Biofil Chemicals and Pharmaceuticals Limited
Who is the CEO of the company?
The CEO is Pavan Singh Rajput.
What is the current market price of the stock?
The current price is ₹46.99.
What is the 52-week price range?
The range is ₹40.4-91.87.
What is the market capitalization of the company?
The market capitalization is ₹76.47 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 139.41.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Biofil Chemicals and Pharmaceuticals Limited (ISIN: INE829A01014) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹76.47 crores and an average daily volume of 30,911 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.